Citius Pharmaceuticals, Inc.
CTXRNASDAQHealthcare● Active
$0.59
+$0.03(+5.21%)
Market Cap$6584015
P/E Ratio—
52W High$2.48
52W Low$0.476
Citius Pharmaceuticals, Inc. (CTXR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTXR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.95
Est. -$0.28 · -238.4%
Revenue
$0.00B
Est. $0.01B · -83.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CTXR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.36 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.28 | -$0.95 | -238.4% | $0.00B | $0.01B | -83.7% |
| ▼ Q1 FY2026 | Feb 13, 2026 | $0.43 | -$0.38 | -188.4% | $0.00B | $0.02B | -78.1% |
| ▼ Q4 FY2025 | Dec 25, 2025 | -$0.24 | -$0.44 | -83.5% | $0.00B | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.24 | -$0.80 | -233.3% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$1.08 | -$1.27 | -17.6% | — | — | — |
| ▼ Q1 FY2025 | Feb 14, 2025 | -$1.25 | -$1.30 | -4.0% | — | $0.00B | — |
| ▼ Q1 FY2025 | Jan 3, 2025 | -$0.04 | -$1.75 | -4275.0% | $0.00B | $0.01B | -97.8% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.95
EPS Est.
-$0.28
EPS Surpr.
-238.4%
Revenue
$0.00B
Q1 FY2026
Feb 13, 2026Miss
EPS Actual
-$0.38
EPS Est.
$0.43
EPS Surpr.
-188.4%
Revenue
$0.00B
Q4 FY2025
Dec 25, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.24
EPS Surpr.
-83.5%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.80
EPS Est.
-$0.24
EPS Surpr.
-233.3%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$1.27
EPS Est.
-$1.08
EPS Surpr.
-17.6%
Revenue
—
Q1 FY2025
Feb 14, 2025Miss
EPS Actual
-$1.30
EPS Est.
-$1.25
EPS Surpr.
-4.0%
Revenue
—
Q1 FY2025
Jan 3, 2025Miss
EPS Actual
-$1.75
EPS Est.
-$0.04
EPS Surpr.
-4275.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q2 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q1 FY2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q4 FY2026 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q2 FY2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -238.4% | $0.72 | $0.70 | -2.72% |
| ▼ Q1 FY2026 | Feb 13, 2026 | -188.4% | $0.79 | $0.77 | -3.55% |
| ▼ Q4 FY2025 | Dec 25, 2025 | -83.5% | $0.80 | $0.84 | +5.02% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -233.3% | $1.25 | $1.30 | +4.00% |
| ▼ Q2 FY2025 | May 14, 2025 | -17.6% | $0.79 | $0.94 | +19.20% |
| ▼ Q1 FY2025 | Feb 14, 2025 | -4.0% | $2.70 | $2.69 | -0.37% |
| ▼ Q1 FY2025 | Jan 3, 2025 | -4275.0% | $3.88 | $3.98 | +2.58% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -20.0% | $19.50 | $17.28 | -11.38% |
Q2 FY2026-2.72%
Report Date
May 15, 2026
EPS Beat/Miss
-238.4%
Price Before
$0.72
Price After
$0.70
Q1 FY2026-3.55%
Report Date
Feb 13, 2026
EPS Beat/Miss
-188.4%
Price Before
$0.79
Price After
$0.77
Q4 FY2025+5.02%
Report Date
Dec 25, 2025
EPS Beat/Miss
-83.5%
Price Before
$0.80
Price After
$0.84
Q3 FY2025+4.00%
Report Date
Aug 12, 2025
EPS Beat/Miss
-233.3%
Price Before
$1.25
Price After
$1.30
Q2 FY2025+19.20%
Report Date
May 14, 2025
EPS Beat/Miss
-17.6%
Price Before
$0.79
Price After
$0.94
Q1 FY2025-0.37%
Report Date
Feb 14, 2025
EPS Beat/Miss
-4.0%
Price Before
$2.70
Price After
$2.69
Q1 FY2025+2.58%
Report Date
Jan 3, 2025
EPS Beat/Miss
-4275.0%
Price Before
$3.88
Price After
$3.98
Q3 FY2024-11.38%
Report Date
Aug 12, 2024
EPS Beat/Miss
-20.0%
Price Before
$19.50
Price After
$17.28
Avg Miss Reaction+1.60%
Beat Rate0 / 8 quarters
Largest Move+19.20% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTXR ends December
Citius Pharmaceuticals, Inc. (CTXR) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.95 — missing the analyst consensus of $-0.28 by -238.4%. The next CTXR earnings date is expected around September 1, 2026.
Each quarter, investors track CTXR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTXR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTXR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTXR earnings · 5 questionsCitius Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CTXR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTXR historically reports after market close (AMC).
CTXR earnings datewhen is CTXR earningsCTXR next earnings datewhen does CTXR report earningsCTXR earnings calendar
▸ Source: FMP · Citius Pharmaceuticals, Inc. SEC filings · US GAAP · Citius Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026